Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

193.51 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5
Open 193.51
Bid (Size) 192.00 (1)
Ask (Size) 193.30 (1)
Prev. Close 193.51
Today's Range 193.51 - 193.51
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+21.08%
+21.08%
1 Month
-1.99%
-1.99%
3 Month
+13.33%
+13.33%
6 Month
+7.99%
+7.99%
1 Year
+25.13%
+25.13%

More News

Read More
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Via Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is ABBVIE INC Ready to Break Out of Its Range?
Via Chartmill
What the Options Market Tells Us About AbbVie
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18,
Via Talk Markets
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Via Benzinga
Topics ETFs
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Via The Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Via The Motley Fool
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Peering Into AbbVie's Recent Short Interest
Via Benzinga
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
Via The Motley Fool
Topics Stocks
Exposures US Equities
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Via Benzinga
3 Things You Need to Know if You Buy AbbVie Stock Today
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
Via The Motley Fool
Earn $1,000 Per Month in Dividends From These 4 Stocks
Via The Motley Fool
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.